Trial Profile
A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Roflumilast (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacodynamics; Proof of concept
- Sponsors Takeda
- 13 Nov 2014 Status changed from recruiting to discontinued ClinicalTrials.gov record.
- 29 Mar 2014 New trial record
- 07 May 2013